目的:分析乳双歧杆菌V9参与的治疗方案改善结直肠癌患者炎症反应的作用。方法:选取医院2022年6月至2024年6月收治的结直肠癌患者当作研究对象,纳入样本量共29例,利用随机分组方法作为分组原则,划分为对照组(纳入该组患者均进行安慰剂 +...目的:分析乳双歧杆菌V9参与的治疗方案改善结直肠癌患者炎症反应的作用。方法:选取医院2022年6月至2024年6月收治的结直肠癌患者当作研究对象,纳入样本量共29例,利用随机分组方法作为分组原则,划分为对照组(纳入该组患者均进行安慰剂 + 奥沙利铂 + 卡培他滨治疗,n = 14)与实验组(入选该组患者均进行乳双歧杆菌V9 + 奥沙利铂 + 卡培他滨治疗,n = 15)。对比两组的炎症因子。结果:实验组4期的IL-6及TLR4低于对照组,2期、4期的IL-12、TNF-α及NF-κB低于对照组(P α、NF-κB及TLR4在不同时间点的变化存在差异(P Objective: To analyze the effect of Bifidobacterium lactis V9 on improving inflammatory response in patients with colorectal cancer. Method: A total of 29 patients with colorectal cancer admitted to the hospital from June 2022 to June 2024 were selected as the study objects. The randomized method was used as the grouping principle to divide them into the control group (all patients in this group were treated with placebo + oxaliplatin + capecitabine, n = 14) and experimental group (all patients in this group were treated with Bifidobacterium lactis V9 + oxaliplatin + capecitabine, n = 15). The inflammatory factors were compared between the two groups. Results: The levels of IL-6 and TLR4 in the experimental group were lower than those in the control group in stage 4, and the levels of IL-12, TNF-α and NF-κB in stage 2 and stage 4 were lower than those in the control group (P α, NF-κB and TLR4 were different at different time points (P Bifidobacterium lactis V9 + oxaliplatin + capecitabine in the clinical treatment of colorectal cancer patients helps reduce inflammation.展开更多
文摘目的:分析乳双歧杆菌V9参与的治疗方案改善结直肠癌患者炎症反应的作用。方法:选取医院2022年6月至2024年6月收治的结直肠癌患者当作研究对象,纳入样本量共29例,利用随机分组方法作为分组原则,划分为对照组(纳入该组患者均进行安慰剂 + 奥沙利铂 + 卡培他滨治疗,n = 14)与实验组(入选该组患者均进行乳双歧杆菌V9 + 奥沙利铂 + 卡培他滨治疗,n = 15)。对比两组的炎症因子。结果:实验组4期的IL-6及TLR4低于对照组,2期、4期的IL-12、TNF-α及NF-κB低于对照组(P α、NF-κB及TLR4在不同时间点的变化存在差异(P Objective: To analyze the effect of Bifidobacterium lactis V9 on improving inflammatory response in patients with colorectal cancer. Method: A total of 29 patients with colorectal cancer admitted to the hospital from June 2022 to June 2024 were selected as the study objects. The randomized method was used as the grouping principle to divide them into the control group (all patients in this group were treated with placebo + oxaliplatin + capecitabine, n = 14) and experimental group (all patients in this group were treated with Bifidobacterium lactis V9 + oxaliplatin + capecitabine, n = 15). The inflammatory factors were compared between the two groups. Results: The levels of IL-6 and TLR4 in the experimental group were lower than those in the control group in stage 4, and the levels of IL-12, TNF-α and NF-κB in stage 2 and stage 4 were lower than those in the control group (P α, NF-κB and TLR4 were different at different time points (P Bifidobacterium lactis V9 + oxaliplatin + capecitabine in the clinical treatment of colorectal cancer patients helps reduce inflammation.
